Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine (Trivalent, Seasonal, Active Ingredient Content: 15 ug HA/Strain/0.5 mL) in Adults and Elderly Persons
Phase of Trial: Phase IV
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Fluart Innovative Vaccines
- 01 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Aug 2011 New trial record